In this seventh installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations to keep in mind when selecting first-line treatment options such as FOLFIRINOX or NALIRIFOX for patients with pancreatic cancer.
In this sixth installment, Tanios Bekaii-Saab, MD, and Shubham Pant, MD, discuss the role cost plays in selecting cancer regimens.
In the final video of this Rapid Reactions series, Beth Sandy, MSN, CRNP, FAPO, discusses data that continue to favor first-line amivantamab plus lazertinib over osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer after a median of 31 months of follow-up.
In this fifth installment, Shubham Pant, MD, and Tanios Bekaii-Saab, MD, discuss the best practices for treating adverse events associated with treatments such as FOLFIRINOX or NALIRIFOX.
In this video, Beth Sandy, MSN, CRNP, FAPO, discusses data showing that zongertinib demonstrated manageable safety and promising efficacy in patients with HER2 aberration-positive solid tumors, including those with baseline brain metastases.
In this video, Beth Sandy, MSN, CRNP, FAPO, discusses ivonescimab, a bispecific antibody targeting PD-1 and VEGF that produced a tolerable safety profile and clinically significant improvement in efficacy compared with pembrolizumab.
To sign up for our newsletter or print publications, please enter your contact information below.
